Jesús Frías

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia, Antonio J. Carcas, Mayte Pérez‐Olmeda et al. · The Lancet · 2021 · 384 citations · Full text

A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe

Alberto M. Borobia, Antonio J. Carcas, Francisco Arnalich et al. · Journal of Clinical Medicine · 2020 · 289 citations · Full text

Dihydropyridine BAY-K-8644 activates chromaffin cell calcium channels

F. Sala, Juan A. Reig, Salvador Viniegra et al. · Nature · 1984 · 261 citations

Dihydropyridine Bay-k-8644, Signal Transduction, Molecular Physiology +7

Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

Belén Gutiérrez‐Gutiérrez, María Dolores del Toro, Alberto M. Borobia et al. · The Lancet Infectious Diseases · 2021 · 98 citations · Full text

Prognostic Evaluation, Disease Progression, Multicentre Cohort Study +11

Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the Biopharmaceutic Classification System

Elena Ramı́rez, Olga Laosa, Pedro Ignacio Cardona Guerra et al. · British Journal of Clinical Pharmacology · 2010 · 82 citations · Full text